Faecalibacterium prausnitzii Antimicrobial Compositions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis are inadequate in effectively inhibiting bacterial growth and virulence, particularly for pathogens like E. coli, and often fail to address the underlying microbiome imbalance.
Innovation Solution
Development of compositions containing heat-stable secreted compounds from Faecalibacterium prausnitzii supernatants, characterized by molecular weights less than 10 kDa, which inhibit bacterial growth and virulence, and are used to treat conditions like acute gastroenteritis, traveler's diarrhea, and inflammatory bowel diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for bacterial infections and inflammatory bowel diseases, then treatment is provided, but they fail to effectively inhibit bacterial growth and virulence, particularly for antibiotic-resistant strains
Solution Approach 1:
The patent extracts and isolates specific heat-stable antimicrobial compounds from F. prausnitzii supernatants with molecular weights less than 10 kDa. This extraction of the active therapeutic components from the whole microbial system allows for targeted inhibition of bacterial growth and virulence factors, particularly effective against antibiotic-resistant strains like E. coli, while maintaining treatment reliability.
Solution Approach 2:
The invention utilizes heat treatment parameters to stabilize and concentrate the antimicrobial compounds. By applying controlled heat to the F. prausnitzii supernatants, the treatment maintains stability of the low molecular weight compounds while eliminating competing factors, thereby enhancing the reliability of bacterial growth inhibition without promoting harmful side effects.
2Reliability
If conventional treatments are used, then treatment is provided, but they fail to address the underlying microbiome imbalance
Solution Approach 1:
The patent employs F. prausnitzii, a beneficial gut microbiota member, as the source of therapeutic compounds. This self-service approach leverages the natural antimicrobial properties of the gut microbiome itself to treat dysbiosis and restore microbiome balance. The heat-stable compounds produced by F. prausnitzii naturally regulate bacterial populations and restore ecological equilibrium in the gut, addressing the root cause rather than just symptoms.
3Object-affected harmful factors
If antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance develops particularly in E. coli strains
Solution Approach 1:
The patent introduces heat-stable antimicrobial compounds from F. prausnitzii as an intermediary substance that mediates bacterial inhibition without causing resistance. These naturally derived compounds from the gut microbiome act as a bridge between the host immune system and pathogenic bacteria, providing growth inhibition through alternative mechanisms that do not select for resistant strains, thereby maintaining long-term therapeutic reliability.
Data Source
AI summary
The present invention relates to antimicrobial compounds isolated from Faecalibacterium prausnitzii supernatants, composition containing the compounds, and their use to inhibit bacterial growth or prevent bacterial infection, inhibit the virulence of N bacteria such as E. coli, and to treat diseases such as irritable bowel disease, Crohn's disease, and ulcerative colitis.